Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neovasc (NVCN) has finalised the design of the Transfemoral Trans-Septal Tiara (TF/TS Tiara) system, for treatment of the heart condition called mitral valve disease.
  • The design freeze of the product now includes a modified, lower profile valve, and a steerable delivery system.
  • The TF/TS Tiara is designed to be minimally invasive, self-anchoring, trackable, and fully retrievable.
  • The company hopes to start a clinical study on the product’s feasibility in late 2020.
  • Neovasc’s share price is down 2.77 per cent, with shares currently trading at $3.51 apiece.

Specialty medical device company Neovasc (NVCN) has finalised the design for the Transfemoral Trans-Septal Tiara (TF/TS Tiara) system.

The Neovasc Tiara device is for treating a heart condition called mitral valve disease, or mitral regurgitation. 

The design freeze for the product includes a number of changes, including a modified, lower profile valve, and a steerable delivery system. These changes may expand the pool of potential patients who are eligible for treatment.

The TF/TS Tiara system’s final design is minimally invasive, self-anchoring, trackable, and fully retrievable. President and CEO of Neovasc, Fred Colen described the product as a potential “best-in-class system.”

The Tiara is currently under clinical investigation in the United States, Canada, Israel, and Europe. Neovasc expects that they will be able to start a clinical study on the product’s feasibility in late 2020.

Neovasc’s share price is down 2.77 per cent, with shares currently trading at $3.51 apiece at 2:43pm EST.

More From The Market Herald

" Revive Therapeutics (CSE:RVV) & PharmaTher (CSE:PHRM) sign MDMA research collaboration agreement

Revive Therapeutics (RVV), and PharmaTher (PHRM) have signed a research collaboration agreement.

" Defence Therapeutics (CSE:DTC) and CQDM to fund new cancer vaccine platform

Defence Therapeutics (DTC) and CQDM to fund the development of a new cancer vaccine platform.

" CENTR (CSE:CNTR) enters esports with an OpTic Gaming Media partnership

CENTR Brands (CNTR) has a new gaming influencer partnership with OpTic Gaming, a global esports and entertainment organization.

" Fobi (TSXV:FOBI) signs new PulseIR deal with Empower Clinics

Fobi AI (FOBI) announced that its wholly-owned subsidiary, PulseIR, has signed a new deal with Empower Clinics.